Molecular breast imaging (MBI) developer Dilon Diagnostics is highlighting a study that suggests MBI is a sensitive technique for diagnosing invasive lobular carcinoma (ILC), a breast cancer that tends to be difficult to detect.
The study was conducted at Legacy Cancer Institute in Portland, OR, and results were published online June 24 in JAMA Surgery. Lead author Dr. Katherine Kelley and colleagues identified 699 patients who had undergone a breast-specific gamma imaging (BSGI) exam on Dilon's molecular imaging system between 2006 and 2012.
BSGI had a sensitivity of 88.9% for diagnosing ILC, slightly higher than the 85.1% reported for detecting invasive ductal carcinoma (IDC), the researchers found. The specificity of the technology for detecting both diseases was comparable, at 78.7% for ILC and 81.8% for IDC, Dilon said.
